Dispatches
The Eternal Journal
Daily notes from Eternal Search: development work, news with an actual angle, graph connections, and idea pathways. No ceremonial optimism required.
Senolytic selectivity needs testing
Patent application US20230330058A1 describes compounds intended to selectively kill senescent cells, but the supplied excerpt provides no quantitative selectivity data or experimental conditions.
A Patent Application Proposes Senolytic Compounds
WO2025186418A1 proposes compounds as senolytics, but the supplied excerpt lacks the experimental details and results needed to assess their claimed selectivity.
uPAR-Targeted T Cells as Senolytics
A patent application describes uPAR-targeted T cells as senolytics, but the available excerpt does not show the evidence needed to assess their selectivity.
Dasatinib and Quercetin in Senolytic Research
Monthly dasatinib plus quercetin treatment reduced senescence-associated gene expression in primate adipose tissue, while each compound's contribution remains unknown.
Senolytic Peptides and the Selectivity Test
A patent describes peptides intended to induce apoptosis in senescent cells, but the available excerpt does not establish whether experiments demonstrated selective killing.
Marco Quarta’s senolytic patent credit
US patent US11026963B2 names Marco Quarta as one of three inventors and records an assignment of rights to Rubedo Life Sciences Inc.
Kirkland, Quercetin and Kidney Injury in Mice
Eternal Search links Kirkland to quercetin through a finding that dasatinib plus quercetin reduced kidney injury in diabetic mice, while his role in the experiment and quercetin's separate contribution remain unknown.
James L. Kirkland and Senolytics
James L. Kirkland helped establish senolytics as a longevity research field focused on selectively eliminating senescent cells.
James L. Kirkland and dasatinib
A mouse kidney finding accompanies the link between Kirkland and dasatinib, but the underlying study, his involvement, and dasatinib's individual contribution remain unknown.
Fisetin and Vascular Cell Senescence
Fisetin reduced senescent endothelial-cell abundance and improved glucose metabolism in obese mice, but the causal relationship and Kirkland's contribution to the study remain unknown.
Steven Austad and Caloric Restriction
Material about Steven Austad mentions an evaluation of caloric restriction, but the available excerpt identifies neither the study nor his role.
Rat responses to 17-alpha-estradiol varied by sex and genotype
Rat responses to 17-alpha-estradiol varied by sex and mitochondrial genotype, but the available material establishes neither lifespan extension nor Steven Austad's role in the study.
Paul Robbins and Senomorphic Effects
Reported reductions in senescence markers and inflammatory secretions are consistent with senomorphic activity, but the excerpt does not establish what happened to the treated cells.
Paul D. Robbins and Senolytics
Robbins's reported coauthorship of navitoclax and fisetin studies connects him to senolytics research, but the available dossier lacks the details needed to assess his specific contribution or potential benefits for humans.
IL-1Ra Expression One Year After Joint Delivery
A phase 1 excerpt reports elevated IL-1Ra expression in joint fluid after one year, while patient benefit and Paul Robbins’s involvement remain unestablished.
A 2.5-Year Reduction in Estimated Biological Age
Exploratory analyses reported a median 2.5-year reduction in estimated biological age after three fasting-mimicking diet cycles, but the available material does not identify the estimation method or establish lasting health benefits.
Caloric Restriction and Measuring Aging
Daniel Belsky studies biological aging measures, but the supplied material leaves his role in CALERIE, the measures assessed, and the trial results unspecified.
Vera Gorbunova and Senolytics
Eternal Search links Vera Gorbunova to the topic of senolytics, but the available excerpt does not establish her scientific contribution to this intervention class.
Vera Gorbunova and Senomorphics
Eternal Search links Vera Gorbunova to senomorphics, which suppress harmful features of cellular senescence, but the supporting excerpt does not establish her research role.
Andrei Seluanov and Wnt Signaling
Eternal Search links Andrei Seluanov to Wnt signaling through a gene-expression observation, but the available evidence establishes neither his involvement nor a decrease in pathway activity.
Andrei Seluanov and Senomorphics
Materials about Andrei Seluanov report fucoidan’s senomorphic effects in cells and aged mice, while leaving his study role and the causal contribution of SIRT6 unresolved.
mTORC1 Inhibition Reduced Survival in Short-Telomere Mice
In telomerase-deficient mice with critically short telomeres, rapamycin or loss of S6 kinase 1 reduced survival, supporting the hypothesis that elevated mTOR activity helps survival in this model.
Rapamycin and Telomere State
Rapamycin extended lifespan in wild-type mice but decreased survival in telomerase-deficient mice with short telomeres, a result directly relevant to Maria Blasco's telomere biology research.
Valter Longo and the Fasting-Mimicking Diet
Valter Longo's research on fasting and nutrient-sensing pathways connects to a limited-nutrient dietary intervention that improved glycaemic control in a 12-month type 2 diabetes trial.
Manuel Serrano and Senolytics
Serrano researches cellular senescence at IRB Barcelona; the Senolytics glossary card describes a six-month nonhuman-primate trial of dasatinib plus quercetin that reduced senescence-marker gene expression and circulating PAI-1 and MMP-9.
Manuel Serrano × Epigenetic Rejuvenation
Manuel Serrano's in vivo reprogramming research connects to epigenetic rejuvenation through a reported ImAge reduction after transient OSKM expression in liver and skeletal muscle, though the organism, experimental design, and tissue function outcomes remai...
Peter de Keizer → FOXO4-DRI
Peter de Keizer's senescent-cell research connects to FOXO4-DRI, a senolytic peptide that induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, with mouse outcomes reported but his exact role and human safety and efficacy not establi...
Peter de Keizer, Senolytics, and the FOXO4-DRI Connection
Peter de Keizer's work on selective senescent-cell elimination via FOXO4-DRI connects him to the senolytic intervention class, as described in the paper 'Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis'.
Peter de Keizer and FOXO Signaling
De Keizer's research profile associates him with FOXO signaling alongside senolytics and FOXO4-DRI, but the specific study establishing this connection is not recorded in the available material.
Marco Demaria and Navitoclax (ABT-263)
Marco Demaria's dossier links him to navitoclax (ABT-263), a BCL-2 family inhibitor and benchmark senolytic administered to eliminate senescent cells, though the specific study and his role remain unidentified.
Marco Demaria and Senolytics
Marco Demaria studies cellular senescence and therapeutic targeting of senescent cells, but the excerpt supporting his connection to senolytics identifies neither the mouse study it describes nor his role in it.
Fahy, Caloric Restriction, and the Mimetic Benchmark
Gregory Fahy's work connects to caloric restriction through the hepatic gene-expression profile that long-term CR produces, used as a molecular benchmark for identifying CR mimetics.
Fahy and Metformin: a caloric-restriction thread
Gregory Fahy's profile is linked to metformin via a finding that eight weeks of treatment reproduced caloric-restriction-like gene-expression changes better than a comparator called CR8, though the original study and Fahy's role remain unknown.
Andrea Maier and NMN: study parameters, no outcomes yet
Andrea Maier, Oon Chiew Seng Professor in Medicine at the National University of Singapore, is linked to NMN through a study excerpt describing 80 middle-aged participants given 300, 600, or 900 mg daily for 60 days; her role and the study's outcomes are no...
Andrea Maier and NAD Metabolism
A trial excerpt supports linking Andrea Maier's profile to NAD metabolism through blood measurements before and after NMN supplementation, but provides neither results nor her role in the trial.
Mehmood Khan and Metformin: the frailty data
Look AHEAD frailty data grounds the Hevolution Foundation CEO's connection to metformin, one of geroscience's best-evidenced longevity candidates.
Jamie Justice and Senolytics
Jamie Justice's geroscience work on biomarkers and clinical trial design connects her to both the D+Q nonhuman-primate senolytic trial and the first-in-human senolytics study, placing her at the boundary between preclinical signal and human evidence.
Jamie Justice and Caloric Restriction
Jamie Justice's profile references an 18-week caloric restriction trial in 58 adults with obesity and prediabetes (10.8 kg mean weight loss, circulating SASP factors measured), but her role in the trial and the significance of the SASP-factor changes for bi...
Jamie Justice and Dasatinib
Jamie Justice's geroscience work on clinical biomarkers connects to the D+Q senolytic protocol tested monthly in nonhuman primates for six months.
Jamie Justice and the D+Q Senolytic Link
Jamie Justice's connection to quercetin traces to a source citing the senolytic combination dasatinib plus quercetin, though her specific role or study is not established.
FLP-17 links glial stress sensing to remote UPR activation
The neuropeptide FLP-17 activates the Unfolded Protein Response in distant C. elegans tissues through glial signaling, a cell-nonautonomous proteostasis mechanism linked to Jennifer Garrison's research on brain-organ communication.
Rubedo Life Sciences' Senolytic Patent
Patent US11026963B2, granted to Rubedo Life Sciences in 2021, describes chemical compositions for selectively killing senescent cells; which compositions carry enforceable protection and whether any has reached human trials remain unestablished from availab...
Navitoclax and sickle cell disease: senolytic hypothesis from St. Jude
A pending St. Jude patent proposes treating sickle cell disease by targeting senescent cells and reports navitoclax restored HSC function in SCD mice; the available excerpt provides no dose, sample size, statistical analysis, or human evidence.
St. Jude Patent Proposes Senolytics for Sickle Cell Disease
A pending St. Jude patent proposes treating sickle cell disease complications with senolytic drugs that selectively eliminate senescent cells; the accessible excerpt does not specify agents, doses, or experimental results.
CAR-T Cells as Senolytics: Targeting uPAR
A 2020 Memorial Sloan Kettering patent application proposes engineered CAR-T cells targeting the surface protein uPAR for selective elimination of senescent cells, placing an immune-cell modality within the senolytic intervention class.
WO2018215795A2: Selective Killing as the Senolytic Criterion
A 2018 patent application from United Kingdom Research and Innovation defines senolytic compounds as agents that selectively kill senescent cells over non-senescent cells, proposing a mechanism through altered signaling pathways that restore or trigger apop...
NAC and glycine: the Baylor glutathione patent
A 2016 WIPO patent from Pharmaplan LLC and Baylor College of Medicine describes a glycine-plus-N-acetylcysteine composition for restoring glutathione levels, with claimed benefits in oxidative stress, mitochondrial fuel oxidation, and mouse lifespan that th...
Glycine paired with NAC to raise glutathione
A 2016 patent publication from Pharmaplan LLC and Baylor College of Medicine describes glycine paired with N-acetylcysteine as a precursor strategy to raise intracellular glutathione levels.
Firmenich patent: AKG against age-associated body odor
Firmenich SA patent CN115996696A proposes alpha-ketoglutarate as a peroxide-reducing ingredient in fragrance formulations intended to limit age-associated body odor; the available excerpt shows POV reduction in oils and fragrance materials.
2003: TOR Signaling Linked to Aging in Nematodes
The Wikipedia timeline of aging research records the first evidence in 2003 that TOR signaling regulates aging in nematodes.
Metformin and the 2007 mouse lifespan finding
The Wikipedia aging research timeline marks 2007 as the year of first evidence that metformin, a diabetes drug, could extend mouse lifespan; the source describes metformin as a longevity candidate linked to the proposed TAME trial but provides no human life...
NMN in the Aging Research Timeline
The Wikipedia 'Timeline of aging research' references NMN as an NAD+ precursor, but the available excerpt provides no further context on which study or result is being discussed.
Insulin/IGF-1 signaling and human longevity genetics
A 2009 entry in the Wikipedia Timeline of aging research records an association between insulin/IGF-1 signaling variants and human longevity; causality was not established.
Rapamycin's 2009 Mouse Result and the Human Evidence Gap
The Wikipedia Timeline of aging research records 2009 as the year rapamycin was shown to extend mouse lifespan; human evidence remains limited to survey studies and a single 48-week trial in healthy adults.
AMPK and the 2004 Nematode Entry
The Wikipedia Timeline of aging research records a 2004 finding that AMP-kinase regulates nematode aging, but the study's authors, design, and mechanism are not established from the available data.
Hayano Lab's Lens Elasticity Finding and Resveratrol
A study co-authored by Hayano Lab members reports that oral resveratrol improved lens elasticity, but the experimental model, dose, and clinical implications remain unknown from the available data.
Timeline enters XPRIZE Healthspan top 100 with Urolithin A
Timeline made the XPRIZE Healthspan top 100 with a Urolithin A product described as a mitophagy activator; formulation, dose, and clinical endpoints are not detailed in the source.
Senolytics Under Scrutiny: De Magalhães and an Open Question
Our system connects João Pedro de Magalhães to senolytics through a source titled 'Senolytics under scrutiny in the quest to slow aging,' but his specific role in the source and his views on senolytic efficacy are unavailable.
Aubrey de Grey and Antagonistic Pleiotropy
A source in Aubrey de Grey's dossier cites growing evidence for antagonistic pleiotropy in mammalian aging, though whether de Grey authored or endorsed the claim is not clear from available data.
Fedichev on Rapamycin: Claim Without Context
Peter Fedichev's texts cite rapamycin as a TOR inhibitor and as part of a combination that produced the greatest lifespan-extending effect, but the combination's composition and experimental model are not disclosed.